Ulcerative Colitis (UC)

Immunology
16
Pipeline Programs
7
Companies
12
Clinical Trials
4 recruiting
8
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
4
8
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
375%
Small Molecule
125%
+ 8 programs with unclassified modality

On Market (8)

Approved therapies currently available

U
ASACOLApproved
mesalamine
Unknown Company
oral1992
AbbVie
ASACOL HDApproved
mesalamine
AbbVie
oral2008
AbbVie
CANASAApproved
mesalamine
AbbVie
Aminosalicylate [EPC]rectal2001
AbbVie
DELZICOLApproved
mesalamine
AbbVie
oral2013
AbbVie
HUMIRAApproved
adalimumab
AbbVie
2002
U
MESALAMINEApproved
mesalamine
Unknown Company
Aminosalicylate [EPC]oral2021
AbbVie
RINVOQApproved
upadacitinib
AbbVie
Janus Kinase Inhibitor [EPC]oral2019
AbbVie
RINVOQ LQApproved
upadacitinib
AbbVie
Janus Kinase Inhibitor [EPC]oral2024

Competitive Landscape

6 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
7 programs
1
1
4
1
AdalimumabPhase 3Monoclonal Antibody1 trial
MesalaminePhase 31 trial
UpadacitinibPhase 3Small Molecule1 trial
risankizumabPhase 3Monoclonal Antibody1 trial
Ravagalimab 600 mgPhase 21 trial
+2 more programs
Active Trials
NCT02738125Completed265Est. Dec 2023
NCT04254783Completed20Est. Oct 2022
NCT03695185Completed42Est. Jan 2022
+4 more trials
Xencor
XencorPASADENA, CA
1 program
1
XmAb942Phase 1/21 trial
Active Trials
NCT06619990RecruitingEst. Jan 2029
A
AltruBioCA - San Francisco
1 program
1
ALTB-268Phase 11 trial
Active Trials
NCT07350577RecruitingEst. Jul 2026
Olympus
OlympusPA - Center Valley
1 program
Colonoscopy after bowel cleansingN/A1 trial
Active Trials
NCT06709209Recruiting300Est. Sep 2027
Pfizer
PfizerNEW YORK, NY
1 program
VelsipityN/A1 trial
Active Trials
NCT07459686Not Yet Recruiting553Est. Jan 2029
Celltrion
CelltrionKorea - Incheon
1 program
Zymfentra (Infliximab-dyyb) REal World Cohort STudyN/A1 trial
Active Trials
NCT07237516RecruitingEst. Nov 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AbbVieMesalamine
AbbVierisankizumab
AbbVieUpadacitinib
AbbVieAdalimumab
AbbVieRavagalimab 600 mg
XencorXmAb942
AltruBioALTB-268
AbbVieRisankizumab
PfizerVelsipity
CelltrionZymfentra (Infliximab-dyyb) REal World Cohort STudy
OlympusColonoscopy after bowel cleansing
AbbVieAssessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

Clinical Trials (12)

Total enrollment: 4,324 patients across 12 trials

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Start: Sep 2025Est. completion: Jul 20260
Phase 3Withdrawn
NCT03398135AbbVierisankizumab

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Start: Aug 2018Est. completion: Feb 20291,242 patients
Phase 3Active Not Recruiting
NCT03006068AbbVieUpadacitinib

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Start: Jan 2017Est. completion: Jul 2027950 patients
Phase 3Active Not Recruiting

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Start: Mar 2014Est. completion: Nov 2019952 patients
Phase 3Completed
NCT03695185AbbVieRavagalimab 600 mg

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Start: Mar 2019Est. completion: Jan 202242 patients
Phase 2Completed

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Start: Oct 2024Est. completion: Jan 2029
Phase 1/2Recruiting

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

Start: Nov 2025Est. completion: Jul 2026
Phase 1Recruiting
NCT04254783AbbVieRisankizumab

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Start: May 2020Est. completion: Oct 202220 patients
Phase 1Completed

An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis

Start: Mar 2026Est. completion: Jan 2029553 patients
N/ANot Yet Recruiting
NCT07237516CelltrionZymfentra (Infliximab-dyyb) REal World Cohort STudy

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Start: Nov 2025Est. completion: Nov 2028
N/ARecruiting
NCT06709209OlympusColonoscopy after bowel cleansing

AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis

Start: Nov 2024Est. completion: Sep 2027300 patients
N/ARecruiting
NCT02738125AbbVieAssessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

Start: Apr 2016Est. completion: Dec 2023265 patients
N/ACompleted

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 4,324 patients
7 companies competing in this space